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Abstract Flatiron (ffe) mice display features of
‘‘ferroportin disease’’ or Type IV hereditary
hemochromatosis. While it is known that both Fe and
Mn metabolism are impaired in flatiron mice, the
effects of ferroportin (Fpn) deficiency on physiological
distribution of these and other biometals is unknown.
We hypothesized that Fe, Mn, Zn and/or Cu distribu-
tion would be altered in ffe/? compared to wild-type
(?/?) mice. ICP-MS analysis showed that Mn, Zn and
Cu levels were significantly reduced in femurs from
ffe/? mice. Bone deposits reflect metal accumulation,
therefore these data indicate that Mn, Zn and Cu
metabolism are affected by Fpn deficiency. The
observations that muscle Cu, lung Mn, and kidney
Cu and Zn levels were reduced in ffe/? mice support
the idea that metal metabolism is impaired. While all
four biometals appeared to accumulate in brains of
flatiron mice, significant gender effects were observed
for Mn and Zn levels in male ffe/? mice. Metals were
higher in olfactory bulbs of ffe/? mice regardless of
gender. To further study brain metal distribution,
54MnCl2 was administered by intravenous injection
and total brain 54Mn was measured over time. At 72 h,
54Mn was significantly greater in brains of ffe/? mice
compared to ?/? mice while blood 54Mn was cleared
to the same levels by 24 h. Taken together, these results
indicate that Fpn deficiency decreases Mn trafficking
out of the brain, alters body Fe, Mn, Zn and Cu levels,
and promotes metal accumulation in olfactory bulbs.
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Introduction
Ferroportin (Fpn; SLC40A1) is a metal exporter
involved in the assimilation of dietary Fe and Mn
(Seo and Wessling-Resnick 2015). Several lines of
evidence suggest it also may function in the transport
of additional metals. Cu treatment induced Fpn
expression and was associated with Fe efflux in J774
macrophage cells (Chung et al. 2004). Troadec et al.
(2010) observed that Zn and Cd also induced Fpn
expression and that this effect was associated with the
binding of Metal Transcription Factor-1 (MTF1) to the
Fpn promoter. Moreover, Fpn appeared to protect cells
from Zn toxicity in this study (Troadec et al. 2010).
Others have shown that Fpn expression in Xenopus
oocytes stimulated efflux of 55Fe, 65Zn, and 57Co and
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that hepcidin, a hormone peptide that down-regulates
Fpn (Nemeth et al. 2004), blocked export of these
metals (Mitchell et al. 2014). These independent lines
of evidence lead to the hypothesis that Fpn plays a role
in the metabolism of metals in addition to Fe and Mn.
Patients with mutations in the Fpn gene develop
hereditary hemochromatosis (HH) type 4, also called
‘‘ferroportin disease’’, which is associated with Fe-
loading and restricted erythropoiesis (Pietrangelo
2004). Substantial effort has been directed towards
developing in vivo models of ferroportin disease.
Mutation of the zebrafish homolog causes defective Fe
transport from the yolk sac to embryo so it is difficult to
translate information about the human disease (Dono-
van et al. 2000). Fpn null mice display embryonic
lethality, and heterozygous Fpnnull/? mice do not load
Fe although they do have mildly impaired Fe home-
ostasis (Donovan et al. 2005). Disruption of intestinal
Fpn confirmed its role in Fe absorption, but these mice
were severely anemic (Donovan et al. 2005). Hepato-
cyte-specific Fpn knockout mice retained liver Fe, but
did not fully recapitulate the phenotype of human
ferroportin disease due to compensating enhancement
of intestinal absorption (Donovan et al. 2005). Tissue
specific disruption of Fpn in macrophages also has
been established, but these mice also developed severe
anemia with Fe retention due to impaired mobilization
after recycling of Fe (Zhang et al. 2012). Flatiron (ffe)
mice have provided a more useful genetic model that
fully recapitulates ferroportin disease. The flatiron
mutation (H32R) was identified in a screen for
ethylnitrosourea-induced mutations that affected
embryonic formation (Zohn et al. 2007). Although
embryos homozygous for this mutation showed severe
anemia and mid-gestational lethality, heterozygous
animals develop the phenotypic characteristics of
ferroportin disease, with reduced hematocrit, hepatic
Fe-loading, high serum ferritin, and low transferrin
saturation (Zohn et al. 2007). Furthermore, the flatiron
mutation H32R shows dominant negative effects much
like other missense mutations in Fpn causing the
human ferroportin disease (Zohn et al. 2007). More
recent studies from our laboratory have shown that Fpn
deficiency impaired Mn metabolism in flatiron mice, a
genetic model of Fpn deficiency (Seo and Wessling-
Resnick 2015). Fpn deficiency reduced intestinal Mn
absorption, and lowered blood, liver, and bile Mn
levels (Seo and Wessling-Resnick 2015). Like Fe, Mn
is both required yet toxic when present in excessive
amounts. In particular, accumulation of Mn in the brain
produces neurotoxic effects disrupting motor function
and behavior (Guilarte 2010).
While the role of Fpn in Fe metabolism has been
established, and its influence on Mn homeostasis
begins to be appreciated, relatively little is known
about the potential impact of Fpn on the distribution of
other metals or how ferroportin disease might alter
metal metabolism. Therefore, we undertook this study
to determine the distribution of Mn, Fe, Zn, and Cu in
relevant tissues and organs collected from heterozy-
gous ffe/? mice. In addition, we evaluated accumu-
lation of brain Mn after intravenous administration of
54Mn in flatiron and wild-type mice.
Materials and methods
Animal care and procedures
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
The protocol used for these studies (Animal Experi-
mentation Protocol IS00000040) was approved by the
Harvard Medical Area Animal Care and Use Commit-
tee. Flatiron (ffe/?) mice were kindly provided by Dr.
Irene E. Zohn (University of Colorado at Denver and
Health Sciences Center, CO). All mice used for these
studies were on the 129S6/SvEvTac background. The
?/? and ffe/? groups were verified by PCR genotyp-
ing (Zohn et al. 2007). Weanling mice were fed a diet
containing 50 mg Fe/kg, 35 mg Mn/kg, 56 mg Zn/kg,
and 10.5 Cu mg/kg (TD120518, Harlan Teklad) until
15 weeks of age. Levels of metals in the diet were as
recommended by American Institute of Nutrition
(Reeves et al. 1993). For trace element analysis, 10
mice/group (6 male and 4 female) were used. Mice were
euthanized under isoflurane inhalation (5 %) followed
by cardiac puncture and exsanguination prior to tissue
collection. All experiments were carried out between
12–3 p.m. in order to avoid circadian effects on Fe
metabolism. Hematocrit and tissue nonheme Fe con-
centrations were measured as previously described (Seo
and Wessling-Resnick 2015).
Mn brain levels were determined after intravenous
administration of 54Mn at 15 weeks of age.
54MnCl2 (Perkin Elmer/NEN, Boston) was diluted to
200 lCi/mL in phosphate-buffered saline (PBS), and
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1.5 mL/kg was injected into the tail vein under
anesthesia with isoflurane. For brain 54Mn levels after
intravenous studies, 5 mice/group (3 male and 2
female) were used. Mice were euthanized by isoflu-
rane overdose 1, 24, or 72 h post-dose of 54MnCl2 to
collect blood and brain tissues. Radioactivity was
quantified in a Packard gamma counter (Cobra Quan-
tum, Packard Instrument, Downers Grove, IL).
Trace element analysis
All samples were handled with special care in order to
avoid environmental contamination. Blood was col-
lected in an anticoagulant (EDTA) tube using heart
puncture with a sterile syringe. After centrifugation at
10009g for 10 min at 4 C, the top yellow plasma
layer was collected, white buffy layer (leukocytes)
was discarded, and erythrocytes were collected. Bone
samples were taken from femurs and excluded the
marrow. Muscle samples were taken from quadriceps.
Samples were analysed for metals by inductively
coupled plasma mass spectrometry (ICP-MS) (Trace
Metals Laboratory, Harvard School of Public Health,
Boston, MA) as described previously (Seo and Wessling-
Resnick 2015). The internal standard was 50 ppb Indium.
Briefly, tissue samples taken from mice were digested with
2 mL/g total wet weight nitric acid (BDH ARISTAR
ULTRA) for 24 h, and then digested with 1 mL/g total wet
weight hydrogen peroxide (BDH Aristar ULTRA) for
24 h at room temperature. Specimens were preserved at
4 C until quantification of metals. Ultrapure water was
used for final sample dilution.
Statistical analysis
Data shown are the mean ± SEM. Statistical com-
parisons were determined with Student’s t test and
two-way ANOVA followed by Bonferroni post hoc
test as appropriate (Prism Graph Pad, Berkeley, CA).
Differences were considered significant at P\ 0.05.
Results
Physiological and haematological characteristics
of flatiron mice
For this study, heterozygous flatiron and wild-type
(?/?) siblings were fed a diet containing 50 mg Fe/
kg, 35 mg Mn/kg, 56 mg Zn/kg, and 10.5 Cu mg/kg
(TD 120518, Harlan Teklad). At 15 weeks of age,
mice were humanely sacrificed to determine the
distribution of metals. Physiological and hematolog-
ical characteristics of ffe/? mice were compared to ?/
? littermates. Body and organ weights in ffe/? mice
were similar to ?/? mice (Table 1) although ffe/
? brain weighed slightly less compared to ?/? mice.
As expected, ffe/? mice had reduced hematocrit
values (P\ 0.05) and higher non-heme Fe levels in
both liver and spleen (P\ 0.05) compared to ?/
? mice (Table 2). There was no difference in food
consumption between the two groups (data not
shown). Consistent with previous studies (Seo and
Wessling-Resnick 2015; Zohn et al. 2007), these data
support the flatiron mouse phenotype associated with
ferroportin disease (Pietrangelo 2004). No significant
difference was detected Cu or Zn levels in erythro-
cytes versus plasma between the two groups (data not
shown). Adjusting for lower haematocrit, the level of
circulating Mn associated with the red blood cell
fraction was significantly reduced in ffe/? mice
compared to ?/? mice (2.5 lg/L vs. 2.9 lg/L,
P = 0.011). This is consistent with our previous
studies showing that flatiron mice displayed reduced
total blood Mn levels at 6, 8, and 16 weeks of age (Seo
and Wessling-Resnick 2015).
Metal distribution in bone and muscle of flatiron
mice
Bone has been used to assess metal accumulation in
humans and mice because metals are incorporated in
Table 1 Physiological characteristics of flatiron (ffe) mice
?/? n ffe/? n
Body weight (g) 25.8 ± 1.806 10 25.5 ± 1.470 10
Brain weight (g) 0.45 ± 0.005 10 0.44* ± 0.003 10
Bone weight (g) 0.14 ± 0.008 10 0.12 ± 0.004 10
Pancreas weight (g) 0.10 ± 0.008 10 0.09 ± 0.009 10
Liver weight (g) 0.88 ± 0.054 10 0.84 ± 0.100 10
Heart weight (g) 0.13 ± 0.008 10 0.13 ± 0.010 10
Lung weight (g) 0.13 ± 0.004 10 0.13 ± 0.004 10
Kidney weight (g) 0.28 ± 0.040 10 0.29 ± 0.025 10
Spleen weight (g) 0.04 ± 0.003 10 0.04 ± 0.002 10
Data are presented as the mean ± SEM; n, no. of mice
* P\ 0.05 between control (?/?) and flatiron mice (ffe/?)
Biometals (2016) 29:147–155 149
123
calcified tissues and therefore subjected to bone
turnover (Gdula-Argasinska et al. 2004). Thus, we
measured the levels of metals in femur and compared
these values to quadriceps muscle. Bone Mn (0.596 vs.
0.788 mg/kg; P = 0.002), Zn (61.079 vs. 77.840 mg/
kg; P = 0.008), and Cu (0.716 vs. 0.941 mg/kg;
P = 0.008) levels were significantly reduced in ffe/
? mice compared to?/? mice (Fig. 1a). Amongst the
metals studied, only Cu levels were significantly
reduced in ffe/? muscle relative to wild-type (Fig. 1b).
Tissue metal levels in flatiron mice
To further explore metal distribution, levels of Mn, Fe,
Zn and Cu were measured in multiple organs. No
differences in Mn, Zn, or Cu were detected in spleen,
heart, and pancreas (data not shown). However,
kidney Zn (24.0 vs. 48.0 mg/kg; P = 0.002) and Cu
(7.5 vs. 10.5 mg/kg; P = 0.018) were reduced in ffe/
? mice compared to ?/? mice (Fig. 2a). Of note,
lung Mn levels were significantly reduced in ffe/
? mice relative to ?/? mice (0.153 mg/kg vs.
0.180 mg/kg; P = 0.01) (Fig. 2b). It is important to
note that the metal content in multiple organs were
similar between ?/? siblings and values reported in
previous studies of mice (summarized in Supplemen-
tal Table 1).
Metal distribution in brain of flatiron mice
Levels of each of the metals were determined for
brain. In addition, olfactory bulbs were dissected and
measured separately from the rest of the brain since the
olfactory bulb is known to be an important brain
region for uptake and/or accumulation of metals
(Sunderman 2001). Indeed, ffe/? olfactory bulbs had
increased content of Mn (0.6496 vs. 0.1616 mg/kg;
P = 0.0006) and Fe (20.4 vs. 7.58 mg/kg; P = 0.05)
compared to ?/? olfactory bulbs (Fig. 3a). Although
not statistically different, Zn levels in olfactory bulbs
were *2.8 fold higher in ffe/? mice compared to ?/
? mice (21.08 vs. 7.41 mg/kg; P = 0.06). Generally,
the brain metal content in flatiron mice was higher for
all of the tested metals, with significant gender
differences observed for Mn and Zn levels, which
were greater in male ffe/? mice compared to male ?/
? mice (Fig. 3b). There were no significant gender
differences between male and female wild-type mice,
or between ffe/? and ?/? female mice.
Brain 54Mn levels after intravenous injection
Amongst the metals studied, Mn is known to accu-
mulate in the brain to produce neurobehavioral effects
(Kern and Smith 2011; Kern et al. 2010). Therefore, to
assess the distribution of this metal from the blood to
the brain we studied the influence of Fpn deficiency on
brain Mn accumulation after intravenous injection of
54MnCl2.
54Mn levels in the brain increased in a time-
dependent manner for both flatiron and wild-type
mice. Levels of 54Mn deposition was greater in ffe/
? at 72 h (Fig. 4). 54Mn clearance from the blood to
peripheral tissues after intravenous metal absorption
occurred rapidly such that similar levels of the
radioisotope are found 24 and 72 h post-injection in
both ffe/? and ?/? mice. Except for the brain,
significant differences in 54Mn deposition into other
tissues were not detected (data not shown).
Discussion
The present study was undertaken to investigate the
influence of Fpn deficiency on the distribution of
metals in the flatiron mouse model of ‘‘ferroportin
disease’’. This disorder is known as type IV
Table 2 Haematological characteristics of flatiron (ffe) mice
?/? n ffe/? n
Hematocrit (%) 49.8 ± 0.416 10 47.2* ± 0.800 10
Liver nonheme iron (lg/mL) 112.9 ± 10.10 10 151.9* ± 12.19 10
Spleen nonheme iron (lg/mL) 571.6 ± 3.149 10 587.0* ± 1.066 10
Data are presented as the mean ± SEM; n, no. of mice
* P\ 0.05 between control (?/?) and flatiron mice (ffe/?)
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hemochromatosis, and arises from mutations in the
human Fpn (SLC40A1) gene. While clinical manifes-
tations of the disease are quite variable, most muta-
tions are inherited as dominant traits. Over 35
polymorphisms are known (Pietrangelo et al. 2011).
Ferroportin disease is associated with mild anemia and
Fe loading in human patients. Consistent with previ-
ous studies (Seo and Wessling-Resnick 2015; Zohn
et al. 2007), flatiron mice used in this investigation
displayed features of both Fe-restricted erythropoiesis
and Fe loading in liver and spleen, recapitulating the
human disease (Pietrangelo 2004).
Both heterozygous ffe/? and ?/? mice weanlings
were fed a diet containing adequate levels to meet but
not exceed nutritional requirements for these essential
yet toxic minerals. Adjusting for reduced haematocrit,
analysis of metal contents in red blood cells and
plasma did not indicate differences between flatiron
and wild-type mice in Zn or Cu. However, the level of
circulating Mn associated with the cell fraction was
significantly reduced in ffe/? mice compared to ?/
? mice. This observation is consistent with our earlier
study that showed reduced total blood Mn in heterozy-
gous flatiron mice as well as reduced red blood cell
superoxide dismutase activity (Seo and Wessling-
Resnick 2015).
Mn is essential for bone health. Along with other
minerals, it is incorporated into calcified tissue
(Gdula-Argasinska et al. 2004). Mn-deficient diets
produce impaired osteoclast activity, alter bone
resorption and skeletal development (Aschner and
Aschner 2005). It has been estimated that nearly 40 %
of body Mn is found in bone, and that excess Mn
increases bone content (O’Neal et al. 2014). Flatiron
mice display reduced bone Mn content, consistent
with the Mn deficiency demonstrated by reduced
blood Mn and superoxide dismutase activity (Seo and
Wessling-Resnick 2015). While Fe levels in bone did
Fig. 1 Metal levels in bone and muscle of wild-type and
flatiron mice. Metal levels were measured by ICP-MS in femurs
(a) and quadriceps muscle (b). Empty and closed bars represent
?/? and ffe/? mice, respectively. Data are mean ± SEM
(n = 6 male and 4 female mice for each genotype). *P\ 0.05
between ?/? versus ffe/? mice; t test
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not change, Zn and Cu were both reduced in femurs
from ffe/? mice compared to ?/? mice. Moreover,
Cu levels in muscle were reduced in ffe/? mice
compared to ?/? mice. Interestingly, kidney Zn and
Cu were also reduced in ffe/? mice compared to ?/
? mice. These combined findings show that Fpn
deficiency can impact the distribution of Zn and Cu
between various organs in the body. They also point to
a possible role of Fpn in resorption or re-absorption of
these metals by bone and kidneys. Because bone is a
good long-term biomarker for metal status, the
reduced levels of Mn, Zn and Cu support the idea
that in addition to Fe, other biometals become depleted
in ferroportin disease. While limited in vitro evidence
supports a role for Fpn in transport of other biometals,
the flatiron mice provide the first in vivo model to test
this hypothesis. Although the simplest hypothesis is
that Fpn itself mediates export of these other metals,
the possibility that loss of iron transport by Fpn affects
other metal regulatory systems cannot be excluded.
Fpn is not only highly expressed in macrophages of
the reticuloendothelial system, intestinal duodenum,
and hepatocytes (Donovan et al. 2000, 2005; Knutson
et al. 2005), but it is also ubiquitously expressed in
murine brain (Boserup et al. 2011), including the
olfactory region (Kim et al. 2013). Both Mn and Fe
accumulated in the olfactory bulbs of flatiron mice.
Although Zn levels were also higher, values were not
statistically different (P = 0.06). Brain Mn metabo-
lism is of particular concern since this metal is
neurotoxic (Roels et al. 2012). A significant route of
entry is uptake of airborne Mn since this metal is
efficiently transported into the body through the nasal
epithelium (Brenneman et al. 2000; Nong et al. 2008;
Tjalve et al. 1996). The accumulation of Mn and Fe in
the olfactory bulbs of flatiron mice suggests that
deficiency of Fpn export function may exacerbate
neurotoxicity caused by exposure to these metals.
To evaluate the role of Fpn in brain metal accumu-
lation, we studied the distribution of 54Mn after
Fig. 2 Kidney and lung metal levels in ffe/? mice. ICP-MS
was used to determine levels of Mn, Fe, Zn and Cu kidney
(a) and lung (b). Empty and closed bars represent ?/? and ffe/
? mice, respectively. Data are mean ± SEM (n = 8–10
mice/group). *P\ 0.05 between ?/? versus ffe/? mice; t-test
152 Biometals (2016) 29:147–155
123
intravenous injection and found that levels of radioiso-
tope were significantly increased in the brain of
flatiron mice 72 h post-injection while circulating
levels were similar to control mice. These data suggest
that Fpn deficiency in flatiron mice enhances accu-
mulation of 54Mn in the brain and are consistent with
the ICP-MS analysis indicating tissue metal levels in
brains of the heterozygous offspring are generally
higher and significantly greater in the olfactory bulb
region. Results of our study indicate that Fpn plays a
role in maintaining steady-state levels of Mn in the
brain and suggest it mediates Mn export from the brain
via the vascular pathway. Further studies are necessary
to more fully define the role of Fpn in blood–brain
transport of Mn and how it contributes to the observed
increases in olfactory bulb and brain metal content.
A major finding from our study is that in addition to
Mn and Fe, aspects of Zn and Cu transport and
Fig. 3 Metal levels in brain of wild-type and flatiron mice.
Olfactory bulbs (a) from 3 to 4 mice of wild-type and flatiron
mice were pooled and determined for metal levels by ICP-MS.
The rest of the brain (b) was determined for metal levels by ICP-
MS. Empty and closed bars represent ?/? and ffe/? mice,
respectively. Data are mean ± SEM (n = 10 mice/group in
panel a; 6 male and 4 female per genotype in panel b).
*P\ 0.05 between ?/? versus ffe/? mice; t-test
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metabolism appear to be affected in the murine model
of ferroportin disease. For example, reduced Zn and
Cu levels in flatiron kidneys imply an important role
for Fpn in renal function. On the other hand, reduced
levels of Mn in the lung could help protect against
infection since this metal has been shown to be critical
to the cellular physiology of pneumococcus (Hood and
Skaar 2012; Kehl-Fie and Skaar 2010) and studies
have shown increased pulmonary susceptibility in
mice to streptococcal infection after Mn inhalation
(Adkins et al. 1980). More problematic would be the
accumulation of Mn and other biometals in brain and
the olfactory bulb discussed above. Patients with
ferroportin disease may be more susceptible to metal
neurotoxicity. Ferroportin disease arises due to several
different missense mutations in the Fpn gene, and is
the only type of hemochromatosis that has a dominant
transmission pattern (Pietrangelo 2004). The disease
has clinical heterogeneity, with marked differences in
type of target cell and Fe accumulation, sub-pheno-
types and degree of penetrance (Pietrangelo 2004).
Ferroportin disease is the second most common cause
of hereditary hemochromatosis (Pietrangelo 2004).
Chronic Mn exposure results in metal accumulation in
specific brain regions associated with Parkinsonian
motor dysfunction (Guilarte 2010; Racette et al.
2001). Our study raises the possibility that patients
with ferroportin disease are more susceptible to Mn
neurotoxicity and neurodegenerative diseases associ-
ated with metal toxicity. In support of this concept, our
recent studies using an in vitro expression system
revealed that ferroportin provides neuroprotection
against Mn toxicity, while flatiron mutant H32R failed
to confer protection (Seo and Wessling-Resnick
2015). These studies suggest that loss of function
mutant H32R leads to increased susceptibility to Mn
toxicity at the cellular level. We are currently explor-
ing the influence of loss of function mutants in
ferroportin disease on metal toxicity in mice.
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